Joseph Whitters joined Solexa’s board of directors, the company said yesterday. He will serve as chairman of the compensation committee.
According to documents filed with the Securities and Exchange Commission yesterday, Whitters will also provide advisory and other consulting services to Solexa as an independent contractor. He will receive a grant of up to 7,500 shares of the company’s unvested common stock. The shares will vest as they are earned through the provision of consulting services, the filing said.
Whitters was chief financial officer at First Health Group and was executive vice president at the time of its sale to Coventry Health Plans. Prior to First Health, he was a controller for United HealthCare and a manager of accounting and taxation at Overland Express.
A former advisory committee participant for NASDAQ, Whitters currently serves on the boards for Mentor, Luminent Mortgage Capital, and Omnicell.
Whitters received his bachelor's degree in accounting from Luther College.
Solexa also said Craig Taylor and Genghis Lloyd-Harris resigned from the board on July 28. According to the SEC filing, the board appointed Stephen Allen and Douglas Fambrough to the audit committee and appointed Mason Morfit as chairman of the nominating and corporate governance committee and chairman of the audit committee.
Deltadot appointed Andrew Carr as chairman of its board this week.
The appointment is effective immediately.
Previously, Carr was a director of Amersham and chief executive officer of Amersham Biosciences. He has been executive chairman and is now the non-executive chairman of Akubio.
He received his PhD in zoology from the University of Nottingham.
Genomic Vision named the company’s founder, Aaron Bensimon, as president and chief executive officer earlier this week.
Bensimon will lead the company with Daniel Nerson, chief operating officer.
He has been the head of the Genome Stability Unit at the Institut Pasteur since 1994.
Bensimon has a PhD in molecular biology from the Weizmann Institute of Science in Israel.
Hybrigenics appointed BioPheresis Technologies CEO Bernhard Ehmer to its supervisory board as a non-executive independent director, the company said earlier this week.
Prior to heading BioPheresis Technologies, he held several positions at Merck, including head of clinical R&D operations, vice-president for oncology, vice-president of corporate strategic planning and alliance management. Ehmer also spent 12 years with Boehringer Mannheim in various clinical R&D and management positions in Germany, Italy and Singapore.